Regulation of cardiometabolic disease by a novel ATP binding cholesterol transporter, ABCA8: A new therapeutic target?

新型 ATP 结合胆固醇转运蛋白 ABCA8 调节心脏代谢疾病：新的治疗靶点？

• 批准号: nhmrc : 1148468
• 负责人: Prof Kerry-Anne Rye
• 金额: $ 21.11万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Targeted Calls
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/regulation-cardiometabolic-disease-therapeutic-target/1321009
• 关键词: Regulation; cardiometabolic; disease; novel; ATP

Approximately 1.7 million Australians and 12% of the population in Singapore has type 2 diabetes (T2D). We have identified a cholesterol transporter, ABCA8, the absence of which produces symptoms similar to those seen in humans with T2D. The aim of this project is to understand the molecular basis of the diabetes symptoms in mice that do not have ABCA8 with a view to identifying this transporter as a drug target to reduce T2D and its complications, including heart attacks.

大约 170 万澳大利亚人和 12% 的新加坡人口患有 2 型糖尿病 (T2D)。我们已经鉴定出一种胆固醇转运蛋白 ABCA8，如果缺乏该蛋白，就会产生与人类 T2D 患者相似的症状。该项目的目的是了解没有 ABCA8 的小鼠糖尿病症状的分子基础，以确定这种转运蛋白作为减少 T2D 及其并发症（包括心脏病发作）的药物靶点。